Mukesh Harisinghani, MD​, presented “Review of the Role of MRI-Targeted Biopsy vs Systematic Biopsy in Prostate Cancer” during the 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 3, 2019 in Boston, Massachusetts.

How to cite: Harisinghani, Mukesh. Review of the Role of MRI-Targeted Biopsy vs Systematic Biopsy in Prostate Cancer” October 3, 2019. Accessed Apr 2024. https://grandroundsinurology.com/review-of-the-role-of-mri-targeted-biopsy-vs-systematic-biopsy/

Review of the Role of MRI-Targeted Biopsy vs Systematic Biopsy in Prostate Cancer – Summary:

Mukesh Harisinghani, MD, Director of the Clinical Discovery Program Center for Molecular Imaging Research at Massachusetts General Hospital, reviews recent research on the effectiveness of MRI-targeted biopsy, as well as systematic biopsy on biopsy-naive prostate cancer patients. Through the analysis of research results, he reveals that there is consistent evidence to support the conclusion that combining the two techniques creates a substantial boost in detection rates. This boost has been proven to be a shift from a 21.4% detection rate in just systematic biopsy and 23.4% in just MRI-targeted biopsy to a detection rate of 27.7% when using combined techniques on biopsy naive patients.

About The 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer:

The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a multi-day, multi-disciplinary forum dedicated to informing healthcare stakeholders about topics including in-vitro fluid- and tissue-based molecular diagnostics, novel observation strategies such as active surveillance, and novel therapeutic interventions. Along with this forum’s efforts to form a consensus on the future of prostate diagnostics and precision care, it aims to create an educational and research strategy for its realization. Dr. Harisinghani presented this lecture during the 4th iteration of this Summit in 2019. 

For additional educational content from this summit, please click here.